OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome

Fecal Calprotectin has become one of the most frequently used biomarkers in patients
suffering from Inflammatory Bowel Diseases. Although its use for monitoring disease activity
and therapeutic efficiency has previously been demonstrated, the test performance should
further be optimized to improve clinical accuracy. The PhiCal™ test is a quantitative ELISA
for measuring, in human stool, concentrations of fecal calprotectin, a neutrophilic protein
that is a marker of mucosal inflammation. The PhiCal™ test can be used as an in vitro
diagnostic to aid in the diagnosis of inflammatory bowel diseases (Crohn's disease and
Ulcerative Colitis), and to differentiate IBD from irritable bowel syndrome. Recently, the
CalproLab™ in vitro device has become available which provides a greater reporting range than
PhiCal™. The OptiCal study aims to test and validate the CalproLab™ assay against the PhiCal™
assay and determine its performance characteristics.

Calprotectin is a valuable clinical marker for inflammation. Calprotectin belongs to a group
of calcium- binding neutrophil-derived proteins. Calprotectin makes up 60% of the cytosolic
proteins within the neutrophil. It is very resistant to bacterial degradation in the gut and
is stable in stool for up to one week

at room temperature. Calprotectin is the noninvasive "test of choice" for quantifying the
degree of GI inflammation and differentiating Irritable Bowel Syndrome (IBS) from
Inflammatory Bowel Disease (IBD).

Inflammatory bowel disease (IBD) is considered to result from interplay between host and
intestinal microbiota. Recently it was shown that the microbiota varied along a gradient of
increasing intestinal inflammation (indicated by calprotectin levels), which was associated
with reduced microbial richness, abundance of butyrate producers, and relative abundance of
Gram-positive bacteria (especially Clostridium clusters IV and XIVa). A significant
association between microbiota composition and inflammation was indicated by a set of
bacterial groups predicting the calprotectin levels. So, intestinal microbiota may represent
a potential biomarker for correlating the level of inflammation and therapeutic responses but
this needs to be further validated.

- This study is a prospective case series during which patients with either Crohn's
disease or ulcerative colitis, Celiac Disease, Irritable Bowel Syndrome and healthy
controls (N=175) will be invited to participate.

- Participants will receive a home kit (with a plain white plastic cup for calprotectin
sample collections) for stool sampling, which then will be returned and processed at
Genova Diagnostics. All participants are required to complete a patient survey, which
will be included in the collection kit.

- Participants will be recruited through the UCLA Division of Digestive Diseases.

- All patients will have confirmation of their diagnosis according to published clinical
guidelines and standards of care using gold standard diagnostics (e.g. endoscopy)

- Stool specimens will be analyzed for fecal Calprotectin using both the CalproLab™ assay
and the PhiCal™ assay. No blood draws or other testing will be performed.

- Patients will undergo a gut microbiome assessment utilizing the GI Effects™ 2200
Comprehensive Profile (Genova Diagnostics).

Inclusion Criteria:

- Male and female IBD patients should have had CD or UC for at least a period of six
months*

- Male and female patients should have had Celiac disease for at least three months.

- Subjects willing and able to sign informed consent

- Subjects willing and able to provide stool sample using a home kit

- IBS patients will meet Rome Foundation criteria and received standard of care
evaluations to exclude other diagnoses

- Healthy controls will consist of patients who do not have any IBD or IBS diagnosis and
meet exclusion criteria for health in nearby table

Exclusion Criteria:

- Unwilling or unable to adhere to the protocol

- Unwilling or unable to adhere to the informed consent

- Age <4y or >65y

- Any of the following conditions by medical history:

- Individuals with intestinal cancer

- Individual taking anti-inflammatory drugs

- Individuals receiving chemotherapy

- Individuals with a known intestinal infection

- Individuals with known upper gastrointestinal disease such as esophagitis or
gastritis that might influence the test's ability to detect intestinal
inflammatory disease.

- Individuals who are scheduled for endoscopy within 24 hours after providing the
sample, or have undergone endoscopy during the 72 hours before providing the
sample.